Electric air taxi company Joby to acquire Blade Air's passenger business

Joby Aviation (JOBY.N) is acquiring Blade Air Mobility's (BLDE.O) passenger business for up to $125 million, a strategic move designed to accelerate the commercial deployment of its electric vertical takeoff and landing (eVTOL) aircraft. This acquisition provides Joby immediate access to Blade's established customer base, operational infrastructure, and a decade of experience, significantly de-risking its path to scaling up electric air taxi services as it pursues FAA certification. Blade's medical organ transplant division will remain a separate entity, rebranded as Strata Critical Medical.

Analysis

Joby Aviation's acquisition of Blade Air Mobility's passenger business for up to $125 million is a strategic maneuver designed to significantly accelerate its go-to-market strategy for its electric air taxi services. This deal provides Joby with immediate access to critical operational assets, including Blade's established customer base, which flew over 50,000 passengers in 2024, and its network of 12 urban terminals in key locations like New York City. By integrating Blade's decade of operating experience and its CEO, Rob Wiesenthal, who will lead the new subsidiary, Joby substantially de-risks its path to commercialization ahead of its anticipated FAA Type Inspection flight testing early next year. The structure of the deal, which separates Blade's medical organ transport division into a new public company, Strata Critical Medical, allows Joby to focus purely on the passenger vertical while still partnering on medical transport. The highly positive sentiment for Joby (0.8) reflects market approval of this strategic shortcut, whereas the neutral sentiment for Blade (0.4) may indicate investor uncertainty regarding the value proposition for the remaining entity or the terms of the sale.

Key Decisions for Investors

• For Joby investors, this acquisition materially de-risks the commercialization roadmap, but focus should remain on the successful completion of the FAA Type Inspection flight testing expected early next year as the next major catalyst.
• Blade investors should reassess their position based on the standalone prospects of the rebranded medical transport entity, Strata Critical Medical, as the neutral sentiment signal suggests the market is uncertain about the value realized from this sale.
• Investors should monitor the integration of Blade's operations and the achievement of performance milestones tied to the $35 million earn-out, as this will be a key indicator of the deal's near-term execution success.
• This transaction could signal a consolidation trend in the nascent eVTOL sector, where acquiring existing helicopter operators becomes a key strategy for accelerating market entry.